111 related articles for article (PubMed ID: 22270402)
1. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma.
Yang B; Lu XC; Yu RL; Chi XH; Zhang WY; Zhu HL; Yuan J; Zhao P
Am J Med Sci; 2012 Apr; 343(4):337-41. PubMed ID: 22270402
[TBL] [Abstract][Full Text] [Related]
2. Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma.
Jabr FI
Int J Hematol; 2005 Nov; 82(4):312-4. PubMed ID: 16298821
[TBL] [Abstract][Full Text] [Related]
3. Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20.
Abou Mourad Y; Taher A; Shamseddine A
Hematol J; 2003; 4(3):222-4. PubMed ID: 12764356
[No Abstract] [Full Text] [Related]
4. [Clinicopathological features of acute tumor lysis syndrome in elderly patients with malignant non-Hodgkin's lymphoma].
Zhang WY; Yang B; Lu XC; Liu Y; Yang Y; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):953-8. PubMed ID: 21867622
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of 18 cases with acute tumor lysis syndrome in children with B-cell lymphoma].
Huang S; Yang J; Zhang R; Duan YL; Zhang YH
Zhonghua Er Ke Za Zhi; 2011 Aug; 49(8):622-5. PubMed ID: 22093429
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
7. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
8. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
9. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
Pfreundschuh M; Poeschel V; Zeynalova S; Hänel M; Held G; Schmitz N; Viardot A; Dreyling MH; Hallek M; Mueller C; Wiesen MH; Witzens-Harig M; Truemper L; Keller U; Rixecker T; Zwick C; Murawski N
J Clin Oncol; 2014 Dec; 32(36):4127-33. PubMed ID: 25403207
[TBL] [Abstract][Full Text] [Related]
10. Tumor lysis syndrome.
Cope D
Clin J Oncol Nurs; 2004 Aug; 8(4):415-6. PubMed ID: 15354929
[No Abstract] [Full Text] [Related]
11. [Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature].
Simon Z; Illés A; Miltényi Z; Magyari F; Váróczy L; Péter N; Gergely L
Orv Hetil; 2012 Oct; 153(42):1658-66. PubMed ID: 23063898
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
16. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
Samochatova EV; Maschan AA; Shelikhova LN; Myakova NV; Belogurova MB; Khlebnikova OP; Shamardina AV; Ryskal OV; Roumiantseva JV; Konovalov DM; Dubrovina ME; Rumyantsev AG
J Pediatr Hematol Oncol; 2014 Jul; 36(5):395-401. PubMed ID: 23823112
[TBL] [Abstract][Full Text] [Related]
17. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
20. Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma.
Park LC; Lee HS; Shin SH; Im H; Ye BJ; Song MK; Oh SY; Lee SM; Lee WS; Kim YS
Acta Haematol; 2011; 125(4):230-6. PubMed ID: 21325812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
